George Cox - Windtree Therapeutics Vice Operations

WINT Stock  USD 0.50  0.01  1.96%   

Executive

George Cox is Vice Operations of Windtree Therapeutics
Age 72
Address 2600 Kelly Road, Warrington, PA, United States, 18976-3622
Phone215 488 9300
Webhttps://windtreetx.com

Windtree Therapeutics Management Efficiency

The company has return on total asset (ROA) of (0.4476) % which means that it has lost $0.4476 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.508) %, meaning that it created substantial loss on money invested by shareholders. Windtree Therapeutics' management efficiency ratios could be used to measure how well Windtree Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -2.98 in 2024. Return On Capital Employed is likely to drop to -0.65 in 2024. Liabilities And Stockholders Equity is likely to gain to about 42.3 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 3.8 M in 2024.
Windtree Therapeutics currently holds 16.83 M in liabilities with Debt to Equity (D/E) ratio of 0.95, which is about average as compared to similar companies. Windtree Therapeutics has a current ratio of 2.42, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Windtree Therapeutics' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Found 6 records

EXECUTIVE Age

Robert HomolkaNeurobo Pharmaceuticals
N/A
Mitchell MDPalisade Bio
46
Johannes MDLixte Biotechnology Holdings
68
Ryker WilliePalisade Bio
N/A
MiKyung KimNeurobo Pharmaceuticals
N/A
Joerg HeyerPalisade Bio
N/A
Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. Windtree Therapeutics, Inc. is a subsidiary of Lees Pharmaceutical Holdings Limited. Windtree Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 33 people. Windtree Therapeutics (WINT) is traded on NASDAQ Exchange in USA. It is located in 2600 Kelly Road, Warrington, PA, United States, 18976-3622 and employs 12 people. Windtree Therapeutics is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Windtree Therapeutics Leadership Team

Elected by the shareholders, the Windtree Therapeutics' board of directors comprises two types of representatives: Windtree Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Windtree. The board's role is to monitor Windtree Therapeutics' management team and ensure that shareholders' interests are well served. Windtree Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Windtree Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
George Cox, Vice Operations
Eric MBA, Senior COO
Jamie McAndrew, Controller, VP
John Tattory, CFO, Senior Vice President
Pratap Paruchuru, Executive Development
Craig Fraser, President CEO, Director
Steven Simonson, Senior Vice President and Chief Development Officer
Ronald Dundore, Ex Quality
MHS MD, Senior Officer
Tracy Rarick, Head Management
Diane Esq, Sr Counsel
John CPA, CFO, VP

Windtree Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Windtree Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Windtree Stock Analysis

When running Windtree Therapeutics' price analysis, check to measure Windtree Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Windtree Therapeutics is operating at the current time. Most of Windtree Therapeutics' value examination focuses on studying past and present price action to predict the probability of Windtree Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Windtree Therapeutics' price. Additionally, you may evaluate how the addition of Windtree Therapeutics to your portfolios can decrease your overall portfolio volatility.